Protalix BioTherapeutics is an Israeli pharmaceutical company whose plant-based enzyme, taliglucerase alfa, has been approved by the U.S. Food and Drug Administration for the treatment of Gaucher disease.
|Key people||Shlomo Yanai (Interim Chairman) Moshe Manor (CEO)|
|Traded as||NYSE MKT: PLX TASE: PLX|
|Total assets||$113.33 million (2013)|
|Revenue||$11.51 million (2013)|
Net Promoter Score is a number from -100 from 100.
The industry average for Health Care / Biotechnology: Biological Products (No Diagnostic Substances) is 0.
Consider an example: If Protalix BioTherapeutics, Inc. sends out NPS surveys immediately after purchase, they are tracking their customers' initial excitement and the checkout experience.
Therefore, comparing the NPS score of Protalix BioTherapeutics, Inc. with your own without any further context is not that useful.
|Vodafone||Telecommunications / Wireless Carrier||-1|
|Chase||Financial Services / Banking||-1|
|CIGNA||Insurance / Health and Life Insurance||-1|
|Comcast||Consumer Brands / Car Manufacturers||-3|
|Telfort||Telecommunications / Wireless Carrier||-3|
|Dish||Telecommunications / Cable/TV service||1|
|Cleeng||Technology / Software||1|
|Fifth Third Bank||Financial Services / Banking||1|
|Accenture Consulting||Technology / Other||1|
|Ocado||Consumer Brands / Grocery||-4|
We have estimated the Net Promoter Score of Protalix BioTherapeutics, Inc. based on the publicly available information
including the sentiment of the company-related tweets, 3rd party reviews, and Alexa ratings.